Product Images Losartan Potassium Tablets, 25 Mg
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Losartan Potassium Tablets, 25 Mg NDC 59746-333 by Jubilant Cadista Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
100mg
This is a medication description for Losartan Potassium USP, available in the form of coated tablets with 100 mg strength. The tablets should be kept out of the reach of children and stored at a temperature range of 15-30°C. The medication is produced by Jublant Caista Pharmaceuticas in Maryland, USA. No additional information is available.*
25mg
This is a medication for Losartan Potassium USP in 25 mg tablets with usual dosage instructions provided in the accompanying package. The medication should be stored at 25°C and kept out of the reach of children. It is manufactured by Jubilant Cadista Pharmaceutical Inc. in the USA and comes in a bottle containing 30 tablets.*
50mg
Losartan Potassium is a medication contained in a bottle with a National Drug Code of 59746-334-30. Each coted ablet contains 50mg of Losatan Potassium USP. The usual dosage of medication is prescribed in the paonet labeled "Losartan Potassium". The Keoptismidmedcaionsotol Tablets are USP quality and come in a bottle that should be kept out of reach of children. The tablets should be protected from light and stored at room temperature (up to 25°C) but are allowed to be stored at a temperature of up to 150°C (66°F). The manufacturer is Cadista, and the package contains 30 tablets. Pharmacies that dispense the medication should accompany it with a patent information leaflet.*
Figure 1 - figure1
Figure 2 - figure2
The text is describing a study that compared the effectiveness of Atenolol and Losartan Potassium in reducing the risk of stroke. The study found that Losartan had a 25% risk reduction compared to Atenolol, with a p-value of 0.001. The graph shows the percentage of patients over the study months.*
Figure 3 - figure3
This appears to be a table showing the primary endpoint events within demographic subgroups for a study comparing the effectiveness of the medications Losartan and Atenolol in treating stroke. The subgroups are broken down by age, gender, race, diabetes status, and history of cardiovascular disease. Each subgroup's number of events, rate, and hazard ratio are listed for both medications. There are symbols proportional to sample size.*
Figure 4.jpg - figure4
The text appears to be a table containing data related to patients and treatment with Losartan Potassium and Placebo. It shows a Risk Reduction of 16.1% with 80 patients experiencing an event. The data is presented in a grid format with columns for the treatment and a timeline of 12, 24, and 48 weeks. Other details are not available from the given text.*
Losartan potassium, USP - structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.